Postdischarge international normalized ratio testing and long-term clinical outcomes of patients with heart failure receiving warfarin: Findings from the ADHERE registry linked to medicare claims

Clinical Cardiology

Volumn 36, Issue 12, 2013, Pages 757-765

  Qualls, Laura G ^a   Greiner, Melissa A ^a   Eapen, Zubin J ^a,b   Fonarow, Gregg C ^c   Mills, Roger M ^d   Klaskala, Winslow ^d   Hernandez, Adrian F ^a,b   Curtis, Lesley H ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICARE; MORTALITY; RETROSPECTIVE STUDY; THROMBOEMBOLISM; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; CHI-SQUARE DISTRIBUTION; DRUG MONITORING; FEMALE; HEART FAILURE; HEART VALVE DISEASES; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; INTERNATIONAL NORMALIZED RATIO; KAPLAN-MEIER ESTIMATE; MALE; MEDICARE; MULTIVARIATE ANALYSIS; PATIENT DISCHARGE; PATIENT READMISSION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; WARFARIN;

EID: 84890121580     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22206     Document Type: Article

References (31)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005; 112: e154-e235.
2. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114: e257-e354.
3. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008; 52: e1-e142.
4. Mountantonakis SE, Grau-Sepulveda MV, Bhatt DL, et al. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. Circ Heart Fail. 2012; 5: 191-201.
5. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133: 160S-198S.
6. Phillips KW, Ansell J,. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther. 2008; 6: 57-70.
7. Bixby MB, Konick-McMahon J, McKenna CG,. Applying the transitional care model to elderly patients with heart failure. J Cardiovasc Nurs. 2000; 14: 53-63.
8. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005; 149: 209-216.
9. Hammill BG, Hernandez AF, Peterson ED, et al. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J. 2009; 157: 995-1000.
10. Kociol RD, Hammill BG, Fonarow GC, et al. Generalizability and longitudinal outcomes of a national heart failure clinical registry: comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. Am Heart J. 2010; 160: 885-892.
11. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864-2870.
12. Rose AJ, Ozonoff A, Henault LE, et al. Anticoagulation for valvular heart disease in community-based practice. Thromb Haemost. 2010; 103: 329-337.
13. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997; 157: 99-104.
14. Zou G., A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004; 159: 702-706.
15. Connock M, Stevens C, Fry-Smith A, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess. 2007;11:iii-iv, ix-66.
16. Bloomfield HE, Krause A, Greer N, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med. 2011; 154: 472-482.
17. Aspinall SL, Zhao X, Handler SM, et al. The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes. J Am Geriatr Soc. 2010; 58: 1475-1480.
18. Desmond D, Kogan P, Underwood S, et al. Performance improvement in managed long-term care: improving warfarin medication management. Home Healthc Nurse. 2009; 27: 150-159.
19. Ansell J, Hollowell J, Pengo V, et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis. 2007; 23: 83-91.
20. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006; 37: 1070-1074.
21. Arnsten JH, Gelfand JM, Singer DE,. Determinants of compliance with anticoagulation: a case-control study. Am J Med. 1997; 103: 11-17.
22. Fang MC, Machtinger EL, Wang F, et al. Health literacy and anticoagulation-related outcomes among patients taking warfarin. J Gen Intern Med. 2006; 21: 841-846.
23. Samsa GP, Matchar DB,. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis. 2000; 9: 283-292.
24. Dolan G, Smith LA, Collins S, et al. Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literature. Curr Med Res Opin. 2008; 24: 1459-1472.
25. Rose AJ, Berlowitz DR, Frayne SM, et al. Measuring quality of oral anticoagulation care: extending quality measurement to a new field. Jt Comm J Qual Patient Saf. 2009; 35: 146-155.
26. Witt DM,. Quality measures and benchmarking for warfarin therapy. J Thromb Thrombolysis. 2011; 31: 242-248.
27. Hernandez AF, Hammill BG, Kociol RD, et al. Clinical effectiveness of anticoagulation therapy among older patients with heart failure and without atrial fibrillation: findings from the ADHERE registry linked to Medicare claims. J Card Fail. 2013; 19: 401-407.
28. Hess PL, Greiner MA, Fonarow GC, et al. Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. Clin Cardiol. 2012; 35: 649-657.
29. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010; 3: 624-631.
30. Pamboukian SV, Nisar I, Patel S, et al. Factors associated with non-adherence to therapy with warfarin in a population of chronic heart failure patients. Clin Cardiol. 2008; 31: 30-34.
31. Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost. 2008; 6: 1500-1506.